SERIOUSLY, THIS EXISTS
This iatrogenic immunodeficiency-associated LPD may regress after withdrawal of the offending antimetabolite, particularly when EBV-positive.
What is methotrexate-associated lymphoproliferative disorder?
In 2026, the FDA approved this regimen for pediatric patients 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma.
What is nivolumab plus AVD?
The canonical Hodgkin immune-evasion amplicon at 9p24.1 simultaneously increases PD-L1/PD-L2 copy number and dosage of this kinase.
What is JAK2?
The prototypic mantle-cell translocation juxtaposes immunoglobulin heavy-chain regulatory elements to this cyclin gene.
What is CCND1?
This acetyltransferase gene is a frequent early FL lesion; its loss perturbs enhancer acetylation, antigen presentation, and immune-synapse biology.
What is CREBBP?
The initial management backbone for many EBV-positive post-transplant B-cell LPDs is reduction of immunosuppression plus this antibody when clinically feasible.
What is rituximab?
In 2025, the FDA approved this ADC with lenalidomide and rituximab for relapsed/refractory LBCL after at least two lines in patient's ineligible for autoHCT or CAR T-cell therapy.
What is brentuximab vedotin?
In EBV-positive classical Hodgkin lymphoma, this latent viral membrane protein mimics CD40 signaling and converges on NF-kB activation.
What is LMP1?
This biologic subtype of mantle cell lymphoma is often SOX11-negative, IGHV-mutated, leukemic/splenic, and more indolent than conventional nodal MCL.
What is Leukemic non-nodal mantle cell lymphoma?
Gain-of-function mutations in this histone methyltransferase create a rational target for tazemetostat in relapsed follicular lymphoma.
What is EZH2?
This type of PTLD expresses CD30 and CD15 expression, weak PAX5, and usually EBV positivity in an immunosuppressed host.
What is classic Hodgkin lymphoma-type PTLD?
In 2025, the FDA approved this CD19 CAR T-cell product for relapsed/refractory marginal zone lymphoma after at least two prior lines of systemic therapy.
What is lisocabtagene maraleucel?
Large 'popcorn' LP cells that are CD20+, BCL6+, OCT2/BOB1+, and usually CD15-/CD30- point to this Hodgkin-adjacent B-cell lymphoma entity.
What is Nodular lymphocyte-predominant B-cell lymphoma?
Across modern MCL series, alteration of this tumor-suppressor pathway is the high-risk feature least rescued by cytarabine-intensive therapy or autologous transplant consolidation.
What is TP53 alteration?
This post-frontline clinical event, not a baseline score, identifies a follicular lymphoma group with strikingly inferior survival after immunochemotherapy.
What is POD24?
This immunodeficiency-associated lymphoma is universally HHV8-positive and often presents as serous effusions in HIV-positive or otherwise immunosuppressed patients.
What is primary effusion lymphoma?
In 2025, the FDA approved this antibody with lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
What is tafasitamab-cxix?
The malignant Hodgkin/Reed-Sternberg cell preserves a crippled B-cell transcriptional signature by showing this transcription factor only weakly, not strongly as in most mature B-cell lymphomas.
What is Dim PAX5?
A cyclin D1-negative, SOX11-positive mantle-cell lymphoma should trigger a search for rearrangements of these alternative cyclin D genes.
What is CCND2 or CCND3?
This mostly pediatric/young-adult FL entity can look cytologically high grade but is usually localized, BCL2-rearrangement negative, and clinically indolent.
What is Pediatric-type follicular lymphoma?
Mutations in SH2D1A encoding SAP cause this inherited syndrome with fulminant EBV infection, HLH, dysgammaglobulinemia, and lymphoma risk.
What is X-linked lymphoproliferative disease type 1?
In 2025, the FDA approved this BTK inhibitor with bendamustine and rituximab for previously untreated mantle cell lymphoma.
What is acalabrutinib?
The S1826-based regimen that displaced BV-AVD for many stage III/IV classical Hodgkin lymphoma patients combines AVD with this PD-1 inhibitor.
What is Nivolumab?
In 2026, this next-generation BCL2 inhibitor became the first FDA-approved BCL2 inhibitor specifically for relapsed/refractory MCL after prior BTK inhibitor exposure.
What is Sonrotoclax?
The inguinal, CD23-positive, BCL2-rearrangement-negative FL variant with frequent STAT6 and 1p36/TNFRSF14 lesions is best thought of as this morphologic variant.
What is Follicular lymphoma with predominantly diffuse growth pattern?